Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii

Frontiers in Microbiology

Volumn 6, Issue MAR, 2015, Pages

  Kuo, Shu Chen ^a,b,c   Lee, Yi Tzu ^a,c   Lauderdale, Tsai Ling Yang ^b   Huang, Wei Cheng ^b   Chuang, Ming Fen ^c   Chen, Chien Pei ^c   Su, Shey Chiang ^d   Lee, Kuan Rong ^e   Chen, Te Li ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Acinetobacter baumannii; Acinetobacter derived cephalosporinase (ADC); Mechanisms of resistance; Sulbactam; Transformation

Indexed keywords

AMPICILLIN; CEFTAZIDIME; CEPHALOSPORINASE; CEPHALOSPORINASE 30; IMIPENEM; MEROPENEM; MESSENGER RNA; RNA; SULBACTAM; TICARCILLIN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PURIFICATION; ENZYME SYNTHESIS; FLOW CYTOMETRY; GENE DOSAGE; GENE SEQUENCE; GENE STRUCTURE; GENETIC TRANSFORMATION; GENETIC VARIABILITY; IMMUNOFLUORESCENCE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACINETOBACTER; ACINETOBACTER BAUMANNII;

EID: 84927559578     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.00231     Document Type: Article

References (27)

1. Adnan, S., Paterson, D. L., Lipman, J., and Roberts, J. A. (2013). Ampicillin/sulbactam: its potential use in treating infections in critically ill patients. Int. J. Antimicrob. Agents 42, 384-389. doi: 10.1016/j.ijantimicag.2013.07.012.
2. OXA-58 gene as a source of high-level resistance to carbapenems in Acinetobacter baumannii. Antimicrob. Agents Chemother. 51, 2324-2328. doi: 10.1128/AAC.01502-06.
3. Blair, J. M., La Ragione, R. M., Woodward, M. J., and Piddock, L. J. (2009). Periplasmic adaptor protein AcrA has a distinct role in the antibiotic resistance and virulence of Salmonella enterica serovar Typhimurium. J. Antimicrob. Chemother. 64, 965-972. doi: 10.1093/jac/dkp311.
4. OXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in Acinetobacter genomic species 13TU. Antimicrob. Agents Chemother. 54, 3107-3112. doi: 10.1128/AAC.00128-10.
5. Chen, T. L., Siu, L. K., Wu, R. C., Shaio, M. F., Huang, L. Y., Fung, C. P., et al. (2007). Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii. Clin. Microbiol. Infect. 13, 801-806. doi: 10.1111/j.1469-0691.2007.01744.x.
6. OXA-58 gene with an upstream IS1008 insertion conferring a high level of carbapenem resistance to Acinetobacter baumannii. Antimicrob. Agents Chemother. 52, 2573-2580. doi: 10.1128/AAC.00393-08.
7. Clinical Laboratory Standards Institute. (2012). Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Second Informational Supplement. CLSI Document M100-S22. Wayne, PA: CLSI.
8. Corbella, X., Ariza, J., Ardanuy, C., Vuelta, M., Tubau, F., Sora, M., et al. (1998). Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J. Antimicrob. Chemother. 42, 793-802. doi: 10.1093/jac/42.6.793.
9. Drawz, S. M., and Bonomo, R. A. (2010). Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160-201. doi: 10.1128/CMR.00037-09.
10. Gales, A. C., Jones, R. N., and Sader, H. S. (2011). Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J. Antimicrob. Chemother. 66, 2070-2074. doi: 10.1093/jac/dkr239.
11. Heritier, C., Poirel, L., and Nordmann, P. (2006). Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii. Clin. Microbiol. Infect. 12, 123-130. doi: 10.1111/j.1469-0691.2005.01320.x.
12. Jacoby, G. A. (2009). AmpC beta-lactamases. Clin. Microbiol. Rev. 22, 161-182. doi: 10.1128/CMR.00036-08.
13. Karageorgopoulos, D. E., and Falagas, M. E. (2008). Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect. Dis. 8, 751-762. doi: 10.1016/S1473-3099(08)70279-2.
14. Ko, W. C., Lee, H. C., Chiang, S. R., Yan, J. J., Wu, J. J., Lu, C. L., et al. (2004). In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J. Antimicrob. Chemother. 53, 393-395. doi: 10.1093/jac/dkh080.
15. Krizova, L., Poirel, L., Nordmann, P., and Nemec, A. (2013). TEM-1 beta-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 68, 2786-2791. doi: 10.1093/jac/dkt275.
16. Kuo, S. C., Chang, S. C., Wang, H. Y., Lai, J. F., Chen, P. C., Shiau, Y. R., et al. (2012). Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect. Dis. 12:200. doi: 10.1186/1471-2334-12-200.
17. OXA-72 in Taiwan. BMC Infect. Dis. 13:319. doi: 10.1186/1471-2334-13-319.
18. Moe, G. R., Tan, S., and Granoff, D. M. (1999). Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun. 67, 5664-5675.
19. Peleg, A. Y., Seifert, H., and Paterson, D. L. (2008). Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538-582. doi: 10.1128/CMR.00058-07.
20. Penwell, W. A., Shapiro, A. B., Giacobbe, R. A., Gu, R. F., Gao, N., Thresher, J., et al. (2015). The molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob. Agents Chemother. 59, 1680-1689. doi: 10.1128/AAC.04808-14.
21. Quale, J., Bratu, S., Gupta, J., and Landman, D. (2006). Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50, 1633-1641. doi: 10.1128/AAC.50.5.1633-1641.2006.
22. Song, J. Y., Kee, S. Y., Hwang, I. S., Seo, Y. B., Jeong, H. W., Kim, W. J., et al. (2007). In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 60, 317-322. doi: 10.1093/jac/dkm136.
23. Tiwari, V., Kapil, A., and Moganty, R. R. (2012). Carbapenem-hydrolyzing oxacillinase in high resistant strains of Acinetobacter baumannii isolated from India. Microb. Pathog. 53, 81-86. doi: 10.1016/j.micpath.2012.05.004.
24. Tiwari, V., Khokar, M. K., Tiwari, M., Barala, S., and Kumar, M. (2014). Anti-bacterial activity of polyvinyl pyrrolidone capped silver nanoparticles on the carbapenem resistant strain of Acinetobacter baumannii. J. Nanomed. Nanotechnol. 5:1000246. doi: 10.4172/2157-7439.1000246.
25. Tiwari, V., and Moganty, R. R. (2014). Conformational stability of OXA-51 beta-lactamase explains its role in carbapenem resistance of Acinetobacter baumannii. J. Biomol. Struct. Dyn. 32, 1406-1420. doi: 10.1080/07391102.2013.819789.
26. Wolff, M., Joly-Guillou, M. L., Farinotti, R., and Carbon, C. (1999). In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob. Agents Chemother. 43, 1406-1411.
27. Zeng, X., and Lin, J. (2013). Beta-lactamase induction and cell wall metabolism in Gram-negative bacteria. Front. Microbiol. 4:128. doi: 10.3389/fmicb.2013.00128.